LCM
FPRX

Landscape Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Landscape Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,673
Closed -$607K – 744
2017
Q4 		$607K Buy
+27,673
New +$890K 0.05% 349
2016
Q3 		– Sell
-15,700
Closed -$649K – 633
2016
Q2 		$649K Buy
+15,700
New +$683K 0.09% 253

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Landscape Capital Management's FPRX Position: Q1 2018 in Review

Landscape Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 27,673 shares — an estimated $607K sold.

Landscape Capital Management first reported a position in FPRX in Q2 2016 and held it in 2 quarters. The position peaked at $649K in Q2 2016. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

  • Landscape Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Landscape Capital Management sold 27,673 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $607K.
  • Landscape Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • Landscape Capital Management's Five Prime Therapeutics, Inc. position peaked at $649K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Landscape Capital Management's 13F filing for Q1 2018, filed 11 May 2018.